IMA - NASDAQ
ImageneBio Inc
$5.69
+2.3%Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
At a Glance
Live Snapshotima
Total Liabilities
Last Annual Value
19.84M
3-Year CAGR
-8%
5-Year CAGR
-41%
10-Year CAGR
-11%
ImageneBio Inc Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 ImageneBio Inc NASDAQ:IMA | 19.84M | -3.9% | -13.1% | N/A | |
 Quince Therapeutics, Inc. NASDAQ:QNCX | 84.33M | -3.9% | 41.9% | N/A | |
 Adicet Bio, Inc. NASDAQ:ACET | 33.15M | -3.7% | -1.5% | -17.8% | |
 MindWalk Holdings Corp. NASDAQ:HYFT | 20.82M | 1.3% | 15.7% | 46.0% | |
 Immunic, Inc. NASDAQ:IMUX | 30.73M | 6.6% | 20.7% | 18.6% | |
 Nutriband Inc. NASDAQ:NTRB | 1.04M | -1.2% | 3.4% | 53.2% | |
 Unicycive Therapeutics, Inc. NASDAQ:UNCY | 18.94M | 1.7% | 53.0% | N/A | |
 Vaxart, Inc. NASDAQ:VXRT | 98.28M | 42.4% | 23.9% | 16.5% | |
 Sutro Biopharma, Inc. NASDAQ:STRO | 306.28M | -1.6% | 28.1% | 6.7% | |
 Ovid Therapeutics Inc. NASDAQ:OVID | 20.27M | -28.8% | 6.5% | 18.4% | |
 Kalaris Therapeutics Inc NASDAQ:KLRS | 42.92M | -3.9% | -6.9% | N/A |
ImageneBio Inc Fair Value Envelope
Related Guides
Continue your IMA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.